JP2018515438A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515438A5 JP2018515438A5 JP2017551629A JP2017551629A JP2018515438A5 JP 2018515438 A5 JP2018515438 A5 JP 2018515438A5 JP 2017551629 A JP2017551629 A JP 2017551629A JP 2017551629 A JP2017551629 A JP 2017551629A JP 2018515438 A5 JP2018515438 A5 JP 2018515438A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- compound according
- optionally
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- IQXWFHDFTAZGNB-UHFFFAOYSA-N CC(OC=C1O)=CC1=O Chemical compound CC(OC=C1O)=CC1=O IQXWFHDFTAZGNB-UHFFFAOYSA-N 0.000 description 1
- YFDRYBUJCGOYCQ-PHDIDXHHSA-N CN1[C@H](C2)CN[C@H]2C1 Chemical compound CN1[C@H](C2)CN[C@H]2C1 YFDRYBUJCGOYCQ-PHDIDXHHSA-N 0.000 description 1
- ZCHCHJQEWYIJDQ-UHFFFAOYSA-N Cc1ncc[o]1 Chemical compound Cc1ncc[o]1 ZCHCHJQEWYIJDQ-UHFFFAOYSA-N 0.000 description 1
- XZGLNCKSNVGDNX-UHFFFAOYSA-N Cc1nnn[nH]1 Chemical compound Cc1nnn[nH]1 XZGLNCKSNVGDNX-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562142589P | 2015-04-03 | 2015-04-03 | |
| US62/142,589 | 2015-04-03 | ||
| PCT/US2016/025531 WO2016161269A1 (en) | 2015-04-03 | 2016-04-01 | Inhibitors of indoleamine 2,3-dioxygenase for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018515438A JP2018515438A (ja) | 2018-06-14 |
| JP2018515438A5 true JP2018515438A5 (enExample) | 2019-05-09 |
Family
ID=55702190
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551629A Withdrawn JP2018515438A (ja) | 2015-04-03 | 2016-04-01 | 癌の治療のためのインドールアミン−２，３−ジオキシゲナーゼの阻害剤およびそれらの使用方法 |
| JP2017551647A Pending JP2018516238A (ja) | 2015-04-03 | 2016-04-01 | 癌の治療のためのインドールアミン−２，３−ジオキシゲナーゼの阻害剤およびそれらの使用方法 |
| JP2017551628A Withdrawn JP2018519245A (ja) | 2015-04-03 | 2016-04-01 | 癌の治療のためのインドールアミン−２，３−ジオキシゲナーゼの阻害剤およびそれらの使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017551647A Pending JP2018516238A (ja) | 2015-04-03 | 2016-04-01 | 癌の治療のためのインドールアミン−２，３−ジオキシゲナーゼの阻害剤およびそれらの使用方法 |
| JP2017551628A Withdrawn JP2018519245A (ja) | 2015-04-03 | 2016-04-01 | 癌の治療のためのインドールアミン−２，３−ジオキシゲナーゼの阻害剤およびそれらの使用方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US10399932B2 (enExample) |
| EP (3) | EP3277670A1 (enExample) |
| JP (3) | JP2018515438A (enExample) |
| KR (3) | KR20170134981A (enExample) |
| CN (3) | CN108093636A (enExample) |
| AR (1) | AR104176A1 (enExample) |
| AU (3) | AU2016242978A1 (enExample) |
| BR (3) | BR112017020895A2 (enExample) |
| CA (3) | CA2981584A1 (enExample) |
| CL (1) | CL2017002494A1 (enExample) |
| CO (1) | CO2017011183A2 (enExample) |
| EA (3) | EA201792204A1 (enExample) |
| HK (1) | HK1247922A1 (enExample) |
| IL (3) | IL254722A0 (enExample) |
| MX (3) | MX2017012729A (enExample) |
| PE (1) | PE20180117A1 (enExample) |
| SG (3) | SG11201807980QA (enExample) |
| TW (1) | TW201700453A (enExample) |
| UY (1) | UY36601A (enExample) |
| WO (3) | WO2016161286A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6602779B2 (ja) | 2014-02-13 | 2019-11-06 | インサイト・コーポレイション | Ｌｓｄ１阻害剤としてのシクロプロピルアミン類 |
| EP3105218B1 (en) | 2014-02-13 | 2019-09-25 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| US9695167B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors |
| KR20170134981A (ko) * | 2015-04-03 | 2017-12-07 | 브리스톨-마이어스 스큅 컴퍼니 | 암의 치료를 위한 인돌아민-2,3-디옥시게나제의 억제제 |
| EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| MY189367A (en) | 2015-08-12 | 2022-02-08 | Incyte Corp | Salts of an lsd1 inhibitor |
| CN108368049A (zh) * | 2015-09-24 | 2018-08-03 | 葛兰素史克知识产权开发有限公司 | 吲哚胺2,3-双加氧酶的调节剂 |
| WO2018116108A1 (en) * | 2016-12-20 | 2018-06-28 | Glaxosmithkline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
| EP3558978A1 (en) * | 2016-12-20 | 2019-10-30 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
| CN114989205A (zh) | 2016-12-22 | 2022-09-02 | 卡里塞拉生物科学股份公司 | 用于抑制精氨酸酶活性的组合物和方法 |
| CA3047002A1 (en) | 2017-01-17 | 2018-07-26 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| WO2018201130A1 (en) * | 2017-04-28 | 2018-11-01 | The Brigham And Women's Hospital, Inc. | Targeting gamma-delta t cells in obesity and cachexia |
| WO2018204532A1 (en) | 2017-05-03 | 2018-11-08 | Vivace Therapeutics, Inc. | Non-fused tricyclic compounds |
| WO2018219309A1 (zh) * | 2017-06-02 | 2018-12-06 | 沈阳化工研究院有限公司 | 一种芳乙烯衍生物及其应用 |
| US20210139467A1 (en) * | 2017-06-28 | 2021-05-13 | Glaxosmithkline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
| CN107325019B (zh) * | 2017-08-11 | 2019-11-22 | 石河子大学 | 芳胺基苯甲酰胺类化合物及n-芳基-芳胺基苯甲酰胺类化合物的制备方法 |
| US11192865B2 (en) | 2017-08-21 | 2021-12-07 | Vivace Therapeutics, Inc. | Benzosulfonyl compounds |
| WO2019078968A2 (en) * | 2017-10-18 | 2019-04-25 | Angex Pharmaceutical, Inc. | CYCLIC COMPOUNDS AS IMMUNOMODULATORS |
| CN109836356B (zh) * | 2017-11-24 | 2022-03-08 | 沈阳化工研究院有限公司 | 一种芳甲醚衍生物及其应用 |
| US11524943B1 (en) | 2017-12-06 | 2022-12-13 | Vivace Therapeutics, Inc. | Benzocarbonyl compounds |
| US11813280B2 (en) | 2018-01-05 | 2023-11-14 | Dicerna Pharmaceuticals, Inc. | Reducing beta-catenin and IDO expression to potentiate immunotherapy |
| US11447449B2 (en) | 2018-01-05 | 2022-09-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US11661403B2 (en) | 2018-05-16 | 2023-05-30 | Vivace Therapeutics, Inc. | Oxadiazole compounds |
| US11186579B2 (en) * | 2018-07-06 | 2021-11-30 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| WO2020018670A1 (en) | 2018-07-17 | 2020-01-23 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| US12059420B2 (en) * | 2018-07-23 | 2024-08-13 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| CN109608334B (zh) * | 2019-01-11 | 2021-07-13 | 盐城通海生物科技有限公司 | 一种合成4-甲氧基巴豆酸甲酯的方法 |
| BR112021014662A2 (pt) * | 2019-02-01 | 2021-09-21 | Glaxosmithkline Intellectual Property Development Limited | Tratamentos de combinação para o câncer que compreendem belantamab mafodotin e um anticorpo anti ox40 e usos e métodos dos mesmos |
| KR102386849B1 (ko) * | 2019-10-14 | 2022-04-13 | 포항공과대학교 산학협력단 | 면역치료를 위한 환경 반응형 접착성 항체전달체 및 이의 제조방법 |
| WO2021102618A1 (en) * | 2019-11-25 | 2021-06-03 | InventisBio Co., Ltd. | Novel salts of indoleamine 2,3-dioxygenase inhibitors |
| CN113214138A (zh) * | 2020-02-04 | 2021-08-06 | 中国医学科学院药物研究所 | 苯丙酸类衍生物、及其制法和药物组合物与用途 |
| US11839659B2 (en) | 2020-07-02 | 2023-12-12 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein |
| CN112174891B (zh) * | 2020-11-02 | 2022-02-01 | 浙江省农业科学院 | 一种氟唑菌苯胺代谢物的制备方法 |
| JP2024016314A (ja) * | 2020-12-24 | 2024-02-07 | 小野薬品工業株式会社 | 一般式（ｉ－ａ）で示される化合物、その薬学的に許容される塩、またはそれらの水和物と免疫チェックポイント阻害薬および／またはｅｐ４受容体拮抗薬との組み合わせ |
| MX2023010371A (es) | 2021-03-05 | 2024-02-12 | Univ Basel | Composiciones para el tratamiento de enfermedades o condiciones asociadas al veb. |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3622337A (en) * | 1968-08-02 | 1971-11-23 | Gaf Corp | Cyan color formers for color photography |
| US4252894A (en) * | 1975-10-22 | 1981-02-24 | Gaf Corporation | Hydrophilic color coupler composition containing diepoxide |
| EP1505966A4 (en) | 2002-05-10 | 2006-08-30 | Bristol Myers Squibb Co | 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA HEMMER |
| CN101445469B (zh) * | 2003-09-24 | 2013-02-13 | 梅特希尔基因公司 | 组蛋白脱乙酰基酶抑制剂 |
| WO2005030705A1 (en) * | 2003-09-24 | 2005-04-07 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| JP5182088B2 (ja) * | 2006-04-19 | 2013-04-10 | アステラス製薬株式会社 | アゾールカルボキサミド誘導体 |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| NO2694640T3 (enExample) | 2011-04-15 | 2018-03-17 | ||
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| EA031470B1 (ru) * | 2013-03-15 | 2019-01-31 | Бристол-Майерс Сквибб Компани | Ингибиторы ido |
| EP2970114B1 (en) * | 2013-03-15 | 2019-05-15 | Bristol-Myers Squibb Company | Ido inhibitors |
| US9758492B2 (en) * | 2013-08-27 | 2017-09-12 | Bristol-Myers Squibb Company | IDO inhibitors |
| KR20170134981A (ko) * | 2015-04-03 | 2017-12-07 | 브리스톨-마이어스 스큅 컴퍼니 | 암의 치료를 위한 인돌아민-2,3-디옥시게나제의 억제제 |
-
2016
- 2016-04-01 KR KR1020177031598A patent/KR20170134981A/ko not_active Withdrawn
- 2016-04-01 EP EP16715777.5A patent/EP3277670A1/en not_active Withdrawn
- 2016-04-01 WO PCT/US2016/025554 patent/WO2016161286A1/en not_active Ceased
- 2016-04-01 EA EA201792204A patent/EA201792204A1/ru unknown
- 2016-04-01 AU AU2016242978A patent/AU2016242978A1/en not_active Abandoned
- 2016-04-01 SG SG11201807980QA patent/SG11201807980QA/en unknown
- 2016-04-01 BR BR112017020895A patent/BR112017020895A2/pt not_active Application Discontinuation
- 2016-04-01 US US15/564,146 patent/US10399932B2/en active Active
- 2016-04-01 AU AU2016242973A patent/AU2016242973A1/en not_active Abandoned
- 2016-04-01 BR BR112017020999A patent/BR112017020999A2/pt not_active Application Discontinuation
- 2016-04-01 UY UY0001036601A patent/UY36601A/es unknown
- 2016-04-01 EP EP16715778.3A patent/EP3277671A1/en not_active Withdrawn
- 2016-04-01 MX MX2017012729A patent/MX2017012729A/es unknown
- 2016-04-01 CN CN201680032165.4A patent/CN108093636A/zh active Pending
- 2016-04-01 HK HK18107390.1A patent/HK1247922A1/zh unknown
- 2016-04-01 EA EA201792231A patent/EA033395B1/ru not_active IP Right Cessation
- 2016-04-01 PE PE2017001828A patent/PE20180117A1/es unknown
- 2016-04-01 SG SG11201708097SA patent/SG11201708097SA/en unknown
- 2016-04-01 KR KR1020177031542A patent/KR20170136557A/ko not_active Withdrawn
- 2016-04-01 EP EP16715779.1A patent/EP3277672A1/en not_active Withdrawn
- 2016-04-01 SG SG11201707948WA patent/SG11201707948WA/en unknown
- 2016-04-01 CN CN201680032158.4A patent/CN107743490A/zh active Pending
- 2016-04-01 EA EA201792186A patent/EA201792186A1/ru unknown
- 2016-04-01 MX MX2017012730A patent/MX2017012730A/es unknown
- 2016-04-01 WO PCT/US2016/025544 patent/WO2016161279A1/en not_active Ceased
- 2016-04-01 TW TW105110690A patent/TW201700453A/zh unknown
- 2016-04-01 JP JP2017551629A patent/JP2018515438A/ja not_active Withdrawn
- 2016-04-01 JP JP2017551647A patent/JP2018516238A/ja active Pending
- 2016-04-01 US US15/564,153 patent/US10399933B2/en active Active
- 2016-04-01 US US15/088,211 patent/US9790169B2/en active Active
- 2016-04-01 AU AU2016243937A patent/AU2016243937A1/en not_active Abandoned
- 2016-04-01 JP JP2017551628A patent/JP2018519245A/ja not_active Withdrawn
- 2016-04-01 CA CA2981584A patent/CA2981584A1/en not_active Abandoned
- 2016-04-01 CN CN201680032102.9A patent/CN107743481A/zh active Pending
- 2016-04-01 CA CA2981660A patent/CA2981660A1/en not_active Abandoned
- 2016-04-01 CA CA2981657A patent/CA2981657A1/en not_active Abandoned
- 2016-04-01 KR KR1020177031596A patent/KR20170134980A/ko not_active Withdrawn
- 2016-04-01 WO PCT/US2016/025531 patent/WO2016161269A1/en not_active Ceased
- 2016-04-01 BR BR112017021021A patent/BR112017021021A2/pt not_active Application Discontinuation
- 2016-04-01 MX MX2017012738A patent/MX2017012738A/es unknown
- 2016-04-01 AR ARP160100897A patent/AR104176A1/es unknown
-
2017
- 2017-05-02 US US15/584,818 patent/US10167254B2/en active Active
- 2017-09-26 IL IL254722A patent/IL254722A0/en unknown
- 2017-09-26 IL IL254720A patent/IL254720A0/en unknown
- 2017-09-26 IL IL254719A patent/IL254719A0/en unknown
- 2017-10-03 CL CL2017002494A patent/CL2017002494A1/es unknown
- 2017-10-31 CO CONC2017/0011183A patent/CO2017011183A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515438A5 (enExample) | ||
| JP2018516238A5 (enExample) | ||
| JP2018519245A5 (enExample) | ||
| JP2016528197A5 (enExample) | ||
| JP2016530283A5 (enExample) | ||
| JP2016518324A5 (enExample) | ||
| JP2017501237A5 (enExample) | ||
| JP2017526726A5 (enExample) | ||
| JP2017502940A5 (enExample) | ||
| JP2016519653A5 (enExample) | ||
| JP2019529484A5 (enExample) | ||
| JP2017508782A5 (enExample) | ||
| JP2015535277A5 (enExample) | ||
| JP2017528498A5 (enExample) | ||
| JP2016520131A5 (enExample) | ||
| JP2016509583A5 (enExample) | ||
| JP2019501125A5 (enExample) | ||
| RU2019119893A (ru) | Ингибиторы jak2 и alk2 и способы их использования | |
| JP2020517616A5 (enExample) | ||
| JP2016513660A5 (enExample) | ||
| JP2016506960A5 (enExample) | ||
| JP2017509689A5 (enExample) | ||
| RU2015143717A (ru) | 2-Аминопиримидин-6-оны и аналоги, проявляющие противораковые и антипролиферативные действия | |
| JP2016513661A5 (enExample) | ||
| JP2009524670A5 (enExample) |